Transcript Asthma
By:Shamsizadeh,Shahrooz
1386.08.23
Respiratory diseases cause loss of 5-38
million days per year.
Asthma is the most common occupational
respiratory disease In under development
countries.
5-10% of U.S member.
15-20% of asthma cause from work.
1.
2.
3.
Airway inflammation
Airway obstruction
Airway hyper responsiveness (+/-)
Reversible obstruction(+/- treatment).
As a consequence of working environment.
Not to stimuli of the outside the work.
Sensitizer-induced O.A(immunologically)
Irritant-induced O.A(non-immunologically)
Aggravation of asthma
High molecular weight
◦
◦
◦
Animal derived
Planet derived
Enzymes
Irritant agents
◦
◦
◦
Chlorine
Acetic acid
Isocyanides
Low molecular weight
◦
◦
◦
◦
◦
Spray paint
Wood dust
Acid anhydride
biocides
Colophony-fluxes
H.M.W is protein & polysaccharide >5kd
Ig-E dependent or not dependent
Mast cell & macrophage
Lym CD4+,IL 4,5,13
L.M.W unknown cause
Hapten (platinum ,isocyanat ,anhydrid)
Platinum is with Ig-E
PMN,Lym CD8+,IL 2,INF
Air way inflammation paramount feature of
asthma.
Air way inflammation cause:
◦ Obstruction
◦ Hypersensitivity
Air way response include:
◦ Rapid(1-2h)
◦ Late (4-8 h)
◦ Dual (1-2 & 4-8 h)
Rapid Airway Dysfunction Syndrome (RADS)
Single high level of exposure to irritant fume ,
gases and smoke.
Short duration between exposure and
response.
Immunologic and neurological inflammation
is the mechanism of RADS.
Is RADS come to asthma?
With onset of 24h
Persistence symptom for at least 12w
Objective evidence of asthma:
◦ Hyper responsiveness
◦ Response to bronchodilator
No previously asthma or COPD
Calcium oxide , nitrogen oxides , welding fumes , spray paint,…
Dose-response relationship
Duration of sensitization(>1 m up to 2year)
and dependent to:
◦ Dose
◦ Duration
◦ Susceptibility
Skin contact (isocyanate) such as respiratory
contact is important.
Environmental agents
(smoking,platinum,O3,diesel gases ,air
allergen.)
1.
2.
Atopy : HMW such as detergent enzymes .
Smoking:
1. platinum worker is the highest risk factor
2. Laboratory animal handler
3. Tetracholorophthalic anhydride.
3.
4.
5.
non-allergic bronchial hyperresponsiveness.
Genetic(diisocyanate, platinum, red cedar)
Upper air way symptom(rhinitis
&conjunctivitis).
Prior asthma and aggregated with work:
1.
2.
3.
4.
5.
6.
Drugs(asprin,beta bloker,tarterazin,sulphit agent)
Environment(O3,SO2,NO2).
Infections(RSV, influenza, para flu, rhinovirus).
Exercise (cold and dry ventilation).
Psychological conditions(vogues and endorphin).
Non active smokers.
Related to:
◦ Air way hyper sensitivity
◦ Severity of asthma
◦ Pharmalogical control of asthma
Patient can come back to work if
◦ Exposure limited
◦ Well treated with drugs
How about sensitized O.A?
Dyspnea ,cough , wheezing.
Some or all of persons involved.
Latency(month to years or acute)
Onset(rapid , late , dual)
History of atopy , rhinitis , conjunctivitis
Environmental investigation
◦ Ventilation , protective devices
◦ Proper usage
1.
2.
3.
4.
5.
6.
Spirometry (base and serial) for work related
↓10% of FEV1 before and after.
Methacholine or histamin challenge test after
10-14 holydays associated with 3time
↑Pc20.
P.E.F serial (the best test for O.A).
Immunological tests(specific IgE→HMW
&platinum)
FeNO, sputum induced analysis(4-6 h and
Eos)
C.X.R
I.
II.
III.
IV.
Occupational symptoms.
Serial P.E.F
Serial spirometry
Challenge test
Current health(during the last 4
weeks)
91% sensitivity and
96 % specificity
If you run or climb stairs fast do you
ever:
•Cough?
•Wheeze?
•Get tight in the chest?
Is you sleep ever broken by:
•Wheeze?
•Difficulty with breathing?
Do you ever wake up in the morning
with:
•wheeze?
•Difficulty with breathing?
Do you ever wheeze:
•If you are in a smoky room?
•If you are in a very dusty place?
Yes/no
Yes/no
Yes/no
Yes/no
Yes/no
Yes/no
Yes/no
Yes/no
Yes/no
1.
2.
3.
4.
5.
6.
7.
8.
Substitution
Ventilation
Change of procedure
Restriction of employment
Free from smoke
Accidental education
Environmental screening
Protective devices
Loss of exposure
Protective devices for RADS and work agg
asthma
Avoid from smoking ,dust ,fume (for irritant)
Follow up with:
a. Serial PFT
b. Specific challenge tests
Step
Symptom
Night
Symptom
Lung
function
medication
STEP 1: Mild
intermittent
Symptoms two times a
week
Asymptomatic and
normal PEF between
exacerbations
two times a
month
FEV1 or PEF 80
percent predicted
PEF variablity <20
percent
Exacerbations may
occur, A course of
systemic
corticosteroids is
recommended.
STEP 2: Mild
persistent
Symptoms > two times
a week but < one time
a day
Exacerbations may
affect activity
> two times a
month
FEV1 or PEF 80
percent predicted
PEF variablity 20 to
30 percent
Lo w-dose inhaled
corticosteroids
STEP 3:
Moderate
persistent
Daily symptoms
Exacerbations two
times a week
> one time a
week
FEV1 or PEF >60
but <80 percent
predicted
PEF variablity >30
percent
Low-to-medium
dose inhaled
corticosteroids and
long-acting inhaled
beta 2-agonists.
STEP 4:
Severe
persistent
Continual symptoms
Limited physical
activity
Frequent exacerbations
Frequent
FEV1 or PEF 60
percent predicted
PEF variablity >30
percent
High-dose inhaled
corticosteroids
AND
Long-acting
inhaled beta 2agonists
Associated with:
◦
◦
◦
◦
◦
Exposure duration
Exposure amount after clinical symptom
Severity of symptoms(by PFT , challenge tests)
Sensitivity to west red cedar , Isocyanides
Corticosteroid inhalation
Reduce exacerbation:
◦ Proper environmental control
◦ Proper education
◦ Proper drug treatment